Contineum Therapeutics

CTNM · NASDAQ

$8.46+$1.02 (+13.71%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.44

Latest news

NewsOct 12, 12:59 PM ETVandana Singh
Why Is Contineum Therapeutics Stock Falling Monday?
NewsSep 30, 9:55 AM ETAvi Kapoor
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
NewsSep 15, 11:07 AM ETVandana Singh
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
NewsSep 15, 8:02 AM ETAvi Kapoor
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Press releaseSep 14, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Press releaseAug 25, 4:05 PM ETBusiness Wire
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
NewsAug 13, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseJul 30, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Press releaseJun 30, 4:05 PM ETBusiness Wire
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Press releaseJun 1, 4:05 PM ETBusiness Wire
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Press releaseMay 15, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 12, 4:05 PM ETBusiness Wire
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Press releaseMay 11, 4:05 PM ETBusiness Wire
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Press releaseMay 5, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Press releaseMay 1, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMay 1, 10:45 AM ETVandana Singh
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar
Press releaseApr 30, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Press releaseMar 13, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NewsMar 5, 4:14 PM ET
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways
Press releaseMar 5, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Press releaseMar 3, 4:05 PM ETBusiness Wire
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Press releaseFeb 18, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJan 28, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NewsJan 13, 12:28 PM ETAvi Kapoor
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday
Press releaseDec 11, 10:24 PM ETBusiness Wire
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
Press releaseDec 11, 4:05 PM ETBusiness Wire
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
Press releaseNov 24, 4:05 PM ETBusiness Wire
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
NewsNov 21, 11:49 AM ETVandana Singh
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value
NewsNov 21, 7:16 AM ET
Market-Moving News for November 21st
Press releaseNov 20, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Press releaseOct 30, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
NewsSep 24, 8:10 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseSep 18, 8:05 AM ETBusiness Wire
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
NewsAug 19, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseAug 5, 4:05 PM ETBusiness Wire
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
Press releaseJun 25, 8:15 AM ETBusiness Wire
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
NewsJan 21, 8:05 AM ETAvi Kapoor
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsDec 12, 8:54 AM ETAvi Kapoor
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
NewsDec 12, 5:41 AM ETAvi Kapoor
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Why Is Contineum Therapeutics Stock Falling Monday?

Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics Q4 Earnings Summary & Key Takeaways

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Market-Moving News for November 21st

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

12 Health Care Stocks Moving In Tuesday's Intraday Session

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket